In
recent times, the copper chalcogenide (Cu2–x
E, E = S, Se, Te, 0 ≤ x ≤ 1)-based
nanomaterials have emerged as potent photothermal agents for photothermal
therapy (PTT) because of their advantageous features, such as the
low cost, reduced toxicity, biodegradability, and strong absorption
of near-infrared (NIR) light in a relatively wide range of wavelength.
Nevertheless, the applicability of Cu2–x
E-based PTT is limited because of its inadequate photothermal
conversion efficiency, as well as insufficient destruction of the
tumor area unexposed to the NIR laser. Fortunately, Cu2–x
E nanomaterials also act as photosensitizers or Fenton-reaction
catalysts to produce reactive oxygen species (ROS), referring to ROS-related
therapy (RRT), which could further eradicate cancer cells to address
the aforementioned limitations of PTT. Moreover, PTT improves RRT
based on photodynamic therapy (PDT), sonodynamic therapy (SDT), chemodynamic
therapy (CDT), and radiotherapy (RT) in different ways. Inspired by
these facts, integrating Cu2–x
E-based
PTT with RRT into a single nanoplatform seems an ideal strategy to
achieve synergistically therapeutic effects for cancer treatment.
Herein, we discuss the synergetic mechanisms, composition, and performances
of recent nanoplatforms for the combination of Cu2–x
E-based PTT and RRT. In addition, we give a brief
overview on some specific strategies for the further improvement of
Cu2–x
E-based PTT and RRT combined
cancer treatment to enable the complete eradication of cancer cells,
such as realizing the imaging-guided synergistic therapy, promoting
deep tumor penetration of the nanosystems, and boosting O2 or H2O2 in the tumor microenvironment. Finally,
we summarize with intriguing perspectives, focusing on the future
tendencies for their clinical application.